Studies Show Bimekizumab Benefits Patients With Hidradenitis Suppurativa
The BE HEARD I and BE HEARD II studies included more than 1000 adults with moderate to severe hidradenitis suppurativa.
The BE HEARD I and BE HEARD II studies included more than 1000 adults with moderate to severe hidradenitis suppurativa.
Risk for postoperative wound infection, complications, hemorrhage no greater with adalimumab versus placebo in hidradenitis suppurativa
Odds higher for HS patients with advancing age, ever smoking, history of depression, comorbidity
Two-part guideline addresses diagnosis, evaluation, management of the chronic inflammatory skin disease
This investigational treatment was evaluated in 42 HS patients, of which 24 had previously failed anti-tumor necrosis factor (TNF) therapy.
The male patient presented in 2009 with a “3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions.”
The authors reported significant disability and comorbidities among patients with HS, including obesity, metabolic syndrome, diabetes, and arthritis.
Highest risk for reduction in HRQoL for hidradenitis suppurativa, blistering conditions, psoriasis